ArticleBioinformation2025
Linking pseudo-exfoliation and serum uric acid among cataract patients.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudo-exfoliation syndrome (PXF), an age-related condition causing fibrillar deposits in the eye, may involve metabolic factors like uric acid. Therefore, it is of interest to compare blood uric acid levels in 80 cataract patients (over 45 years) at R.L. Jalappa Hospital, Kolar, from January to December 2024, splitting them into 40 with PXF and 40 without, excluding those with secondary PXF, other eye conditions, systemic diseases affecting uric acid, or prior eye surgery and collecting age, sex and uric acid data from medical records. No significant differences were found in mean age (70.83 years for PXF vs. 69.15 years for controls; p=0.332) or sex distribution (p=0.809). However, uric acid was higher in the PXF group (4.513 mg/dL) than controls (3.908 mg/dL; p=0.016), rising with PXF severity: 3.76 mg/dL (mild), 4.49 mg/dL (moderate) and 5.29 mg/dL (severe; p=0.001). Elevated uric acid is linked to PXF presence and severity, suggesting a role in its development, though further studies are needed to confirm clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.